Substrate for development of atrial fibrillation in patients with congestive heart failure: are we close to the answer?
Platonov
Pyotr G
PG
D000200:Action Potentials; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000209:etiology* / Q000503:physiopathology*; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D005260:Female; D006325:Heart Atria / Q000166:cytology / Q000503:physiopathology; D006333:Heart Failure / Q000150:complications* / Q000503:physiopathology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D032383:Myocytes, Cardiac / Q000502:physiology*; D018408:Patch-Clamp Techniques; D015221:Potassium Channels; D012307:Risk Factors; D018487:Ventricular Dysfunction, Left / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology* / Q000601:surgery
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D002121:Calcium Channel Blockers; D015221:Potassium Channels